Kronos Bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. Leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, Kronos utilizes its small molecule microarray (SMM) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.
- Norbert Bischofberger, PhD President & Chief Executive Officer
- Angela Koehler, PhD Scientific Founder; Assistant Professor, Koch Institute for Integrative Cancer Research (MIT)
- Christopher Wilfong Chief Operating Officer